Table 6.
Univariate analyses for overall survival in Alaska Native gastric cancer patients.
| Patient Characteristics | HR | 95% CI | P a |
|---|---|---|---|
| Age, >55 vs. <55 yr | 0.60 | 0.38–0.96 | 0.031 |
| Sex, male vs. female | 1.13 | 0.72–1.79 | 0.601 |
| Signet ring, absent vs. present | 0.62 | 0.36–1.08 | 0.089 |
| Lauren type, diffuse vs. intestinal | 0.99 | 0.63–1.55 | 0.953 |
| Grade, G2 vs. G3 | 1.67 | 0.92–3.03 | 0.089 |
| Anatomic site | 0.404 | ||
| Cardia b | 1.00 | ||
| Noncardia c | 0.69 | 0.33–1.43 | |
| Overlap/NOS | 0.68 | 0.38–1.21 | |
| AJCC Stage | <0.0001 | ||
| I | 1.00 | ||
| II | 1.52 | 0.71–3.28 | |
| III | 1.90 | 0.82–4.40 | |
| IV | 6.16 | 3.11–12.20 | |
| Treatment | <0.0001 | ||
| Chemo | 1.00 | ||
| None | 2.19 | 1.22–3.95 | |
| Neoadjuvant, surgery | 0.20 | 0.09–0.43 | |
| Surgery only | 0.36 | 0.17–0.78 | |
| Surgery, adjuvant | 0.39 | 0.17–0.93 | |
| Neoadjuvant, surgery, adjuvant | 0.11 | 0.03–0.37 | |
| Mutation, no vs. yes | 1.41 | 0.80–2.48 | 0.232 |
| TP53 mutation, no vs. yes | 1.05 | 0.64–1.72 | 0.857 |
| PIK3CA mutation, no vs. yes | 1.57 | 0.86–2.84 | 0.139 |
| MMR, stable vs. deficient | 1.40 | 0.67–2.93 | 0.374 |
| COX-2, low vs. high | 2.37 | 1.27–4.43 | 0.007 |
| MUC1, low vs. high | 1.24 | 0.65–2.37 | 0.518 |
| TA-MUC1, low vs. high | 1.42 | 0.84–2.38 | 0.188 |
| HER2, negative vs. positive | 1.13 | 0.88–1.45 | 0.322 |
| PD-L1 CPS, <1 vs. >1 | 1.05 | 0.58–1.89 | 0.871 |
| EBV, negative vs. positive | 1.28 | 0.74–2.22 | 0.373 |
a Bold type indicates statistical significance (p < 0.05). b Cardia includes gastroesophageal junction, fundus. c Noncardia includes, body, pylorus, and antrum. Abbreviations: HR, hazard ratio; CI, confidence interval; NOS, not otherwise specified; AJCC, American Joint Committee on Cancer; MMR, mismatch repair; COX-2 cyclooxygenase 2; MUC1 mucin 1; CPS, combined positive score. TA-MUC1, tumor-associated MUC1.